Psychotomimesis Mediated by κ Opiate Receptors
The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
The κ opioid agonists are analgesics that seem to be free of undesired morphine-like effects. Their dysphoric actions observed with the κ agonist cyclazocine are thought to be mediated by an action at σ-phencyclidine receptors. The benzomorphan κ agonist MR 2033 is inactive at σ-phencyclidine receptors. In male subjects, the opiate-active (-)-isomer, but not the (+)-isomer, elicited dose-dependent dysphoric and psychotomimetic effects that were antagonized by naloxone. Thus, κ opiate receptors seem to mediate psychotomimetic effects. In view of the euphorigenic properties of μ agonists, our results imply the existence of opposed opioid systems affecting emotional and perceptual experiences.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“agonism of κ-opioid receptors were shown to produce depression-like symptoms in humans (Pfeiffer et al., 1986).”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Pfeiffer et al., 1986
In the citing paper
“Nonetheless, the three receptor types have different behavioral domains, with MOR and DOR mediating generally positive motivation and affect, while KOR mediates generally negative motivation and aversion (Pfeiffer et al 1986; Shippenberg et al 1987; Pecina and Berridge 2000; McLaughlin et al 2003; for reviews see Van Ree et al 2000; Le Merrer et al 2009).”
From The behavioral, anatomical and pharmacological parallels between social attachment, love and addiction (2012) · cites this paper as Pfeiffer et al 1986
In the citing paper
“Kappa receptor agonists induce anxiogenic and dysphoric effects in humans (141-143) and depressive-like behavior in animals (i.e., increased immobility in the forced swim test) (144, 145).”
From A brain-centric model of suicidal behavior (2020) · cites this paper as [141]
Citations
Cites
(1976) · Medical Entomology and Zoology · Cited by 8,899
Martin, W. R., Eades, C. G., Thompson, J. A., Huppler, R. E., & Gilbert, P. E. (1976) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)30536-7 · Cited by 2,992
Pharmacologic effects of CI‐581, a new dissociative anesthetic, in man
Domino, E. F., Chodoff, P., & Corssen, G. (1965) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt196563279 · Cited by 748
Martin, W. R. (1983) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06637-2 · Cited by 648
Thrills in response to music and other stimuli
Goldstein, A. (1980) · Physiological Psychology · doi:10.3758/bf03326460 · Cited by 522
Mucha, R. F., & Herz, A. (1985) · Psychopharmacology · doi:10.1007/bf00432213 · Cited by 510
Self-citationThe binding spectrum of narcotic analgesic drugs with different agonist and antagonist properties
Magnan, J., Paterson, S. J., Tavani, A., & Kosterlitz, H. W. (1982) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/bf00495865 · Cited by 509
A CLASSIFICATION OF OPIATE RECEPTORS THAT MEDIATE ANTINOCICEPTION IN ANIMALS
TYERS, M. B. (1980) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1980.tb07041.x · Cited by 341
Opiate receptor binding sites in human brain
Pfeiffer, A., Pasi, A., Mehraein, P., & Herz, A. (1982) · Brain Research · doi:10.1016/0006-8993(82)91150-7 · Cited by 298
Self-citationPhencyclidine (angel dust)/sigma "opiate" receptor: visualization by tritium-sensitive film.
Quirion, R., Hammer, R. P., Herkenham, M., & Pert, C. B. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.9.5881 · Cited by 254
Research works printed but not linked: 6
- Jasinski, D. R., Drug Addiction 1: 216 (1977).
- MARTIN, W.R., PHARMACOL REV 35: 283 (1984).
- MARTIN, W.R., SUBSTANCE AND ALCOHOL ACTIONS/MISUSE 1: 269 (1980).
- Shearman, G. T., Drug Discrimination: Application in CNS Pharmacology: 37 (1982).
- VAUPEL, D.B., FAILURE OF NALTREXONE (NTX) TO ANTAGONIZE PHENCYCLIDINE (PCP) AND THE OPIOID SKF-10047 (SKF) IN THE DOG, FEDERATION PROCEEDINGS 41: 1333 (1982).
- Zerssen, D. V., Assessment of Depression: 270 (1985).
Cited by
A Role for Brain Stress Systems in Addiction
Koob, G. F. (2008) · Neuron · doi:10.1016/j.neuron.2008.06.012 · Cited by 1,056
“Dynorphin has long been hypothesized to mediate negative emotional states. k receptor agonists produce place aversions (Shippenberg et al., 2007) and depression and dysphoria in humans (Pfeiffer et al., 1986).”
Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway.
Spanagel, R., Herz, A., & Shippenberg, T. S. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.6.2046 · Cited by 1,014
Self-citationMu, delta, and kappa opioid receptor mRNA expression in the rat CNS: An in situ hybridization study
Mansour, A., Fox, C. A., Burke, S., Meng, F., Thompson, R. C., Akil, H., & Watson, S. J. (1994) · Journal of Comparative Neurology · doi:10.1002/cne.903500307 · Cited by 870
Salvinorin A: A potent naturally occurring nonnitrogenous κ opioid selective agonist
Roth, B. L., Baner, K., Westkaemper, R., Siebert, D., Rice, K. C., Steinberg, S., Ernsberger, P., & Rothman, R. B. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182234399 · Cited by 784
Neurobiological mechanisms for opponent motivational processes in addiction
Koob, G. F., & Le Moal, M. (2008) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2008.0094 · Cited by 702
Alcoholism: A Systems Approach From Molecular Physiology to Addictive Behavior
Spanagel, R. (2009) · Physiological Reviews · doi:10.1152/physrev.00013.2008 · Cited by 634
Exploring the opioid system by gene knockout
Kieffer, B. L., & Gavériaux-Ruff, C. (2002) · Progress in Neurobiology · doi:10.1016/s0301-0082(02)00008-4 · Cited by 620
Cloning and functional comparison of kappa and delta opioid receptors from mouse brain.
Yasuda, K., Raynor, K., Kong, H., Breder, C. D., Takeda, J., Reisine, T., & Bell, G. I. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.14.6736 · Cited by 618
The Dysphoric Component of Stress Is Encoded by Activation of the Dynorphin κ-Opioid System
Land, B. B., Bruchas, M. R., Lemos, J. C., Xu, M., Melief, E. J., & Chavkin, C. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.4458-07.2008 · Cited by 601
Biological substrates of reward and aversion: A nucleus accumbens activity hypothesis
Carlezon, W. A., & Thomas, M. J. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.06.075 · Cited by 561
The dynorphin/kappa opioid system as a modulator of stress-induced and pro-addictive behaviors
Bruchas, M. R., Land, B. B., & Chavkin, C. (2010) · Brain Research · doi:10.1016/j.brainres.2009.08.062 · Cited by 544
“Building on this prior work and early evidence that implicated a role for the KOR in producing dysphoric responses in humans (Pfeiffer et al., 1986), studies using neurochemical and electrophysiological methods demonstrated that KOR activation in mesolimbic structures including the ventral…”
ResultPliakas, A. M., Carlson, R. R., Neve, R. L., Konradi, C., Nestler, E. J., & Carlezon, W. A. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-18-07397.2001 · Cited by 509
“Synthetic agonists cause dysphoria in humans (Pfeiffer et al., 1986), and intra-NAc microinjections of these agents establish place aversions in rats (Bals-Kubik et al., 1993).”
BackgroundAntidepressant-Like Effects of κ-Opioid Receptor Antagonists in the Forced Swim Test in Rats
Mague, S. D., Pliakas, A. M., Todtenkopf, M. S., Tomasiewicz, H. C., Zhang, Y., Stevens, W. C., Jones, R. M., Portoghese, P. S., & Carlezon, W. A. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.046433 · Cited by 485
Addiction as a stress surfeit disorder
Koob, G. F., Buck, C. L., Cohen, A., Edwards, S., Park, P. E., Schlosburg, J. E., Schmeichel, B., Vendruscolo, L. F., Wade, C. L., Whitfield, T. W., et al. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.05.024 · Cited by 483
“Dynorphins produce aversive dysphoric-like effects in animals and humans and have been hypothesized to mediate negative emotional states (Shippenberg et al., 2007; Wee and Koob, 2010; Mucha and Herz, 1985; Pfeiffer et al., 1986).”
BackgroundDynorphin, stress, and depression
Knoll, A. T., & Carlezon, W. A. (2010) · Brain Research · doi:10.1016/j.brainres.2009.09.074 · Cited by 465
Sex differences in neural mechanisms mediating reward and addiction
Becker, J. B., & Chartoff, E. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-018-0125-6 · Cited by 459
Neurobiological substrates for the dark side of compulsivity in addiction
Koob, G. F. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.07.043 · Cited by 458
The dark side of emotion: the addiction perspective
Koob, G. F. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.11.044 · Cited by 433
“Dynorphins produce aversive dysphoric-like effects in animals and humans and have been hypothesized to mediate negative emotional states (Shippenberg et al., 2007; Wee and Koob, 2010; Mucha and Herz, 1985; Pfeiffer et al., 1986).”
BackgroundMcLaughlin, J. P., Marton-Popovici, M., & Chavkin, C. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-13-05674.2003 · Cited by 430
Cloning and pharmacological characterization of a rat kappa opioid receptor.
Meng, F., Xie, G. X., Thompson, R. C., Mansour, A., Goldstein, A., Watson, S. J., & Akil, H. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.21.9954 · Cited by 426
Koob, G. F. (2011) · Current topics in behavioral neurosciences · doi:10.1007/7854_2011_129 · Cited by 423
Simonin, F., Valverde, O., Smadja, C., Slowe, S., Kitchen, I., Dierich, A., Le Meur, M., Roques, B. P., Maldonado, R., & Kieffer, B. L. (1998) · The EMBO Journal · doi:10.1093/emboj/17.4.886 · Cited by 418
The Mechanism of Action of Novel Antipsychotic Drugs
Meltzer, H. Y. (1991) · Schizophrenia Bulletin · doi:10.1093/schbul/17.2.263 · Cited by 411
The role of the dynorphin–κ opioid system in the reinforcing effects of drugs of abuse
Wee, S., & Koob, G. F. (2010) · Psychopharmacology · doi:10.1007/s00213-010-1825-8 · Cited by 398
Addiction is a Reward Deficit and Stress Surfeit Disorder
Koob, G. F. (2013) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2013.00072 · Cited by 397
Carlezon, W. A., Béguin, C., DiNieri, J. A., Baumann, M. H., Richards, M. R., Todtenkopf, M. S., Rothman, R. B., Ma, Z., Lee, D. Y.-W., & Cohen, B. M. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.092304 · Cited by 390
Dynorphin and the pathophysiology of drug addiction
Shippenberg, T. S., Zapata, A., & Chefer, V. I. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.06.011 · Cited by 387
Kreek, M. J., LaForge, K. S., & Butelman, E. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd897 · Cited by 374
Dynorphin Acts as a Neuromodulator to Inhibit Itch in the Dorsal Horn of the Spinal Cord
Kardon, A. P., Polgár, E., Hachisuka, J., Snyder, L. M., Cameron, D., Savage, S., Cai, X., Karnup, S., Fan, C. R., Hemenway, G. M., et al. (2014) · Neuron · doi:10.1016/j.neuron.2014.02.046 · Cited by 369
Structure of the Nanobody-Stabilized Active State of the Kappa Opioid Receptor
Che, T., Majumdar, S., Zaidi, S. A., Ondachi, P., McCorvy, J. D., Wang, S., Mosier, P. D., Uprety, R., Vardy, E., Krumm, B. E., et al. (2018) · Cell · doi:10.1016/j.cell.2017.12.011 · Cited by 365
Cole, R. L., Konradi, C., Douglass, J., & Hyman, S. E. (1995) · Neuron · doi:10.1016/0896-6273(95)90225-2 · Cited by 365
Opioid receptors: drivers to addiction?
Darcq, E., & Kieffer, B. L. (2018) · Nature Reviews Neuroscience · doi:10.1038/s41583-018-0028-x · Cited by 352
Distinct subpopulations of nucleus accumbens dynorphin neurons drive aversion and reward
Al-Hasani, R., McCall, J. G., Shin, G., Gomez, A. M., Schmitz, G. P., Bernardi, J. M., Pyo, C.-O., Park, S. I., Marcinkiewcz, C. M., Crowley, N. A., et al. (2015) · Neuron · doi:10.1016/j.neuron.2015.08.019 · Cited by 345
“Previous studies reported that the dyn/KOR system mediates negative emotional states likely through increased dyn release in the NAc, contributing to the dysphoria associated with depression, drug dependence, and withdrawal, but the mechanisms for engagement of dyn circuitry were unknown (Britton et al., 1982; Bruchas…”
Backgroundκ opioids selectively control dopaminergic neurons projecting to the prefrontal cortex
Margolis, E. B., Lock, H., Chefer, V. I., Shippenberg, T. S., Hjelmstad, G. O., & Fields, H. L. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0511159103 · Cited by 325
Molecular alterations in the neostriatum of human cocaine addicts
Hurd, Y. L., & Herkenham, M. (1993) · Synapse · doi:10.1002/syn.890130408 · Cited by 323
Kinase cascades and ligand-directed signaling at the kappa opioid receptor
Bruchas, M. R., & Chavkin, C. (2010) · Psychopharmacology · doi:10.1007/s00213-010-1806-y · Cited by 317
Addiction and Stress: An Allostatic View
Koob, G. F., & Schulkin, J. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2018.09.008 · Cited by 315
Burkett, J. P., & Young, L. J. (2012) · Psychopharmacology · doi:10.1007/s00213-012-2794-x · Cited by 307
“Nonetheless, the three receptor types have different behavioral domains; MOR and DOR mediate generally positive motivation and affect, while KOR mediates generally negative motivation and aversion (Pfeiffer et al. 1986; Shippenberg et al. 1987; Pecina and Berridge 2000; McLaughlin et al. 2003; for reviews, see Van Ree…”
Reviewing the ketamine model for schizophrenia
Frohlich, J., & Van Horn, J. D. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881113512909 · Cited by 303
Land, B. B., Bruchas, M. R., Schattauer, S., Giardino, W. J., Aita, M., Messinger, D., Hnasko, T. S., Palmiter, R. D., & Chavkin, C. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0910705106 · Cited by 301
Chronic pain induces anxiety with concomitant changes in opioidergic function in the amygdala
Narita, M., Kaneko, C., Miyoshi, K., Nagumo, Y., Kuzumaki, N., Nakajima, M., Nanjo, K., Matsuzawa, K., Yamazaki, M., & Suzuki, T. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300858 · Cited by 289
30 years of dynorphins — New insights on their functions in neuropsychiatric diseases
Schwarzer, C. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.05.006 · Cited by 289
Peckys, D., & Landwehrmeyer, G. B. (1999) · Neuroscience · doi:10.1016/s0306-4522(98)00251-6 · Cited by 278
Effects of κ-opioid receptor ligands on intracranial self-stimulation in rats
Todtenkopf, M. S., Marcus, J. F., Portoghese, P. S., & Carlezon, W. A. (2004) · Psychopharmacology · doi:10.1007/s00213-003-1680-y · Cited by 273
“Moreover, humans report that k-opioid agonists cause states of dysphoria (Pfeiffer et al. 1986; Roth et al. 2002), another symptom of clinical depression.”
BackgroundNeural Systems Underlying Opiate Addiction
De Vries, T. J., & Shippenberg, T. S. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-09-03321.2002 · Cited by 270
Bruchas, M. R., Schindler, A. G., Shankar, H., Messinger, D. I., Miyatake, M., Land, B. B., Lemos, J. C., Hagan, C. E., Neumaier, J. F., Quintana, A., et al. (2011) · Neuron · doi:10.1016/j.neuron.2011.06.011 · Cited by 267
Nucleus Accumbens μ-Opioid Receptors Mediate Social Reward
Trezza, V., Damsteegt, R., Achterberg, E. J. M., & Vanderschuren, L. J. M. J. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.5492-10.2011 · Cited by 263
“, 1995b) and intra-NAc administration of -opioid receptor agonists is related to the well known dysphoric effects of -opioid receptor agonists (Pfeiffer et al., 1986; van Ree et al., 1999; Le Merrer et al., 2009).”
BackgroundEnadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans
Walsh, S., Strain, E., Abreu, M., & Bigelow, G. (2001) · Psychopharmacology · doi:10.1007/s002130100788 · Cited by 258
Role of kappa-opioid receptors in stress and anxiety-related behavior
Van’t Veer, A., & Carlezon, W. A. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3195-5 · Cited by 257
Interactions between Kappa Opioid Agonists and Cocaine: Preclinical Studies
Mello, N. K., & Negus, S. S. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06678.x · Cited by 247
Interaction of the Chiral Forms of Ketamine with Opioid, Phencyclidine, σ and Muscarinic Receptors
Hustveit, O., Maurset, A., & Øye, I. (1995) · Pharmacology & Toxicology · doi:10.1111/j.1600-0773.1995.tb01041.x · Cited by 246
Non-suicidal self-injurious behavior, endogenous opioids and monoamine neurotransmitters
Stanley, B., Sher, L., Wilson, S., Ekman, R., Huang, Y.-Y., & Mann, J. J. (2010) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.10.028 · Cited by 246
Brust, T. F., Morgenweck, J., Kim, S. A., Rose, J. H., Locke, J. L., Schmid, C. L., Zhou, L., Stahl, E. L., Cameron, M. D., Scarry, S. M., et al. (2016) · Science Signaling · doi:10.1126/scisignal.aai8441 · Cited by 240
μ-Opposing actions of the κ-opioid receptor
Pan, Z. Z. (1998) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(98)01169-9 · Cited by 238
Stress-induced reinstatement of cocaine seeking is mediated by the kappa opioid system
Redila, V. A., & Chavkin, C. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1122-y · Cited by 234
The antidepressant effect of running is associated with increased hippocampal cell proliferation
Bjørnebekk, A., Mathé, A. A., & Brené, S. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145705005122 · Cited by 231
A Review of the Nonmedical Use of Ketamine: Use, Users and Consequences
Jansen, K. L. R. (2000) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2000.10400244 · Cited by 228
Neurocircuitry of alcohol addiction
(2014) · Handbook of Clinical Neurology · doi:10.1016/b978-0-444-62619-6.00003-3 · Cited by 225
The Kappa Opioid Receptor: From Addiction to Depression, and Back
Lalanne, L., Ayranci, G., Kieffer, B. L., & Lutz, P.-E. (2014) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2014.00170 · Cited by 225
Knoll, A. T., Meloni, E. G., Thomas, J. B., Carroll, F. I., & Carlezon, W. A. (2007) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.127415 · Cited by 225
McLaughlin, J. P., Land, B. B., Li, S., Pintar, J. E., & Chavkin, C. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300860 · Cited by 225
Historical review: Opioid receptors
Snyder, S. H., & Pasternak, G. W. (2003) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(03)00066-x · Cited by 221
kappa-Opioid receptor signaling and brain reward function
Bruijnzeel, A. W. (2009) · Brain Research Reviews · doi:10.1016/j.brainresrev.2009.09.008 · Cited by 214
A brain-centric model of suicidal behavior
Mann, J. J., & Rizk, M. M. (2020) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20081224 · Cited by 214
Qu, C., King, T., Okun, A., Lai, J., Fields, H. L., & Porreca, F. (2011) · Pain · doi:10.1016/j.pain.2011.03.002 · Cited by 214
Stein, C., Millan, M. J., Yassouridis, A., & Herz, A. (1988) · European Journal of Pharmacology · doi:10.1016/0014-2999(88)90511-0 · Cited by 211
Self-citationMillière, R. (2017) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2017.00245 · Cited by 206
Drug-Induced Conditioned Place Preference and Its Practical Use in Substance Use Disorder Research
McKendrick, G., & Graziane, N. M. (2020) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2020.582147 · Cited by 205
Bruchas, M. R., Land, B. B., Lemos, J. C., & Chavkin, C. (2009) · PLoS ONE · doi:10.1371/journal.pone.0008528 · Cited by 204
White, K. L., Robinson, J. E., Zhu, H., DiBerto, J. F., Polepally, P. R., Zjawiony, J. K., Nichols, D. E., Malanga, C. J., & Roth, B. L. (2015) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.216820 · Cited by 203
Delta and Kappa Opioid Receptors as Suitable Drug Targets for Pain
Vanderah, T. W. (2010) · The Clinical Journal of Pain · doi:10.1097/ajp.0b013e3181c49e3a · Cited by 198
κ-opioid receptor/dynorphin system: genetic and pharmacotherapeutic implications for addiction
Butelman, E. R., Yuferov, V., & Kreek, M. J. (2012) · Trends in Neurosciences · doi:10.1016/j.tins.2012.05.005 · Cited by 192
Quock, R. M., Burkey, T. H., Varga, E. V., Hosohata, Y., Hosohata, K., Cowell, S. M., Slate, C. A., Ehlert, F. J., Roeske, W. R., & Yamamura, H. I. (1999) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01416-9 · Cited by 192
Wang, Y., Tang, K., Inan, S., Siebert, D., Holzgrabe, U., Lee, D. Y. W., Huang, P., Li, J.-G., Cowan, A., & Liu-Chen, L.-Y. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.073668 · Cited by 191
Endogenous opioid system dysregulation in depression: implications for new therapeutic approaches
Peciña, M., Karp, J. F., Mathew, S., Todtenkopf, M. S., Ehrich, E. W., & Zubieta, J.-K. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0117-2 · Cited by 190
Fulfilling the Promise of "Biased" G Protein–Coupled Receptor Agonism
Luttrell, L. M., Maudsley, S., & Bohn, L. M. (2015) · Molecular Pharmacology · doi:10.1124/mol.115.099630 · Cited by 190
Rosoff, D. B., Smith, G. D., & Lohoff, F. W. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.3554 · Cited by 186
Development of κ Opioid Receptor Antagonists
Carroll, F. I., & Carlezon, W. A. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm301783x · Cited by 185
Kappa Opioid Receptor-Induced Aversion Requires p38 MAPK Activation in VTA Dopamine Neurons
Ehrich, J. M., Messinger, D. I., Knakal, C. R., Kuhar, J. R., Schattauer, S. S., Bruchas, M. R., Zweifel, L. S., Kieffer, B. L., Phillips, P. E. M., & Chavkin, C. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.2444-15.2015 · Cited by 184
Jutras-Aswad, D., DiNieri, J. A., Harkany, T., & Hurd, Y. L. (2009) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-009-0027-z · Cited by 184
Orexin/hypocretin role in reward: implications for opioid and other addictions
Baimel, C., Bartlett, S. E., Chiou, L., Lawrence, A. J., Muschamp, J. W., Patkar, O., Tung, L., & Borgland, S. L. (2015) · British Journal of Pharmacology · doi:10.1111/bph.12639 · Cited by 179
The dynorphin/κ-opioid receptor system and its role in psychiatric disorders
Tejeda, H. A., Shippenberg, T. S., & Henriksson, R. (2011) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-011-0844-x · Cited by 179
Cellular mechanism for anti-analgesic action of agonists of the κ-opioid receptor
Pan, Z. Z., Tershner, S. A., & Fields, H. L. (1997) · Nature · doi:10.1038/38730 · Cited by 176
Mechanisms of ketamine and its metabolites as antidepressants
Hess, E. M., Riggs, L. M., Michaelides, M., & Gould, T. D. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114892 · Cited by 175
Zhu, J., Luo, L.-Y., Li, J., Chen, C., & Liu‐Chen, L. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36877-6 · Cited by 175
Li, J., Luo, L.-Y., Krupnick, J. G., Benovic, J., & Liu‐Chen, L. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.17.12087 · Cited by 170
Evaluation of Opioid Modulation in Major Depressive Disorder
Ehrich, E., Turncliff, R., Du, Y., Leigh-Pemberton, R., Fernandez, E., Jones, R., & Fava, M. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2014.330 · Cited by 169
“Neuropsychopharmacology to m-receptor agonism, k-receptor agonism has been associated with adverse effects on mood in humans (Pfeiffer et al, 1986; Wadenberg, 2003) and rodents (Carlezon et al, 2009; Mague et al, 2003).”
BackgroundDevelopment of Functionally Selective, Small Molecule Agonists at Kappa Opioid Receptors
Zhou, L., Lovell, K. M., Frankowski, K. J., Slauson, S. R., Phillips, A. M., Streicher, J. M., Stahl, E. L., Schmid, C. L., Hodder, P., Madoux, F., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.504381 · Cited by 169
A review of the role of anti‐opioid peptides in morphine tolerance and dependence
Rothman, R. B. (1992) · Synapse · doi:10.1002/syn.890120206 · Cited by 168
Effects of Kappa Opioids on Cocaine Self-Administration by Rhesus Monkeys
Negus, S. S., Mello, N. K., Portoghese, P. S., & Lin, C.-E. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36769-2 · Cited by 167
Kappa-opioid ligands in the study and treatment of mood disorders
Carlezon, W. A., Béguin, C., Knoll, A. T., & Cohen, B. M. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.05.008 · Cited by 167
Ebner, S. R., Roitman, M. F., Potter, D. N., Rachlin, A. B., & Chartoff, E. H. (2010) · Psychopharmacology · doi:10.1007/s00213-010-1836-5 · Cited by 166
Rorick‐Kehn, L. M., Witkin, J. M., Statnick, M. A., Eberle, E. L., McKinzie, J. H., Kahl, S. D., Forster, B. M., Wong, C. J., Li, X., Crile, R. S., et al. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.09.021 · Cited by 166
Prescription Opioid Analgesics Increase the Risk of Depression
Scherrer, J. F., Svrakic, D. M., Freedland, K. E., Chrusciel, T., Balasubramanian, S., Bucholz, K. K., Lawler, E. V., & Lustman, P. J. (2014) · Journal of General Internal Medicine · doi:10.1007/s11606-013-2648-1 · Cited by 165
CI‐977, a novel and selective agonist for the κ‐opioid receptor
Hunter, J. C., Leighton, G. E., Meecham, K., Boyle, S. J., Horwell, D. C., Rees, D. C., & Hughes, J. (1990) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1990.tb12110.x · Cited by 164
Pattern of use and subjective effects of Salvia divinorum among recreational users
González, D., Riba, J., Bouso, J. C., Gómez-Jarabo, G., & Barbanoj, M. J. (2006) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2006.04.001 · Cited by 163
Salvinorin A: the ‘magic mint’ hallucinogen finds a molecular target in the kappa opioid receptor
Sheffler, D. J., & Roth, B. L. (2003) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(03)00027-0 · Cited by 163
Chang, P.-C., Pollema-Mays, S. L., Centeno, M. V., Procissi, D., Contini, M., Baria, A. T., Martina, M., & Apkarian, A. V. (2014) · Pain · doi:10.1016/j.pain.2014.02.019 · Cited by 161
“The direct and indirect pathways are associated with positive hedonic and aversion/negative affect, respectively [15,52,57,58].”
BackgroundZhang, H., Kranzler, H. R., Yang, B.-Z., Luo, X., & Gelernter, J. (2008) · Molecular Psychiatry · doi:10.1038/sj.mp.4002035 · Cited by 160
Knoll, A. T., Muschamp, J. W., Daws, S. E., Ferguson, D., Dietz, D., Meloni, E. G., Carroll, F. I., Nestler, E. J., Konradi, C. L., & Carlezon, W. A. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.03.017 · Cited by 160
Metadata
- Authors
- Pfeiffer, A., Brantl, V., Herz, A., & Emrich, H. M.
- Affiliations
- LMU Klinikum (DE)
- Boehringer Ingelheim (Germany) (DE)
- Max Planck Society (DE)
- Max Planck Institute of Psychiatry (DE)
- ORCID
- Pfeiffer, Andreas
- Venue
- Science
- Published
- 1986-08-15
- Volume
- 233
- Issue
- 4765
- Pages
- 774-776
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2032643119
- Cited by
- 857
- References
- 30
- Citations by year
- 2026: 20 · 2025: 19 · 2024: 23 · 2023: 17 · 2022: 18 · 2021: 38 · 2020: 42 · 2019: 21 · 2018: 27 · 2017: 24 · 2016: 37 · 2015: 38 · 2014: 30 · 2013: 35 · 2012: 41
- FWCI
- 4.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacological Receptor Mechanisms and Effects
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- psychotomimetic effects, kappa opioid receptor, kappa opioid receptor agonists, cyclazocine, naloxone antagonism, stereoisomers, mu-opioid receptor agonists, euphoria, analgesia
- MeSH terms
- Adult, Anxiety, Benzomorphans, Humans, Male, Middle Aged, Morphinans, Naloxone, Personality Tests, Phencyclidine, Receptors, Opioid, Receptors, Opioid, kappa
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.